v3.23.1
COMBINED AND CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Hyperfine Convertible Preferred Stock
Liminal Convertible Preferred Stock
Additional Paid-in Capital
Accumulated Deficit
Common Stock
Class A Common Stock
Common Stock
Class B Common Stock
Balance at Dec. 31, 2020 $ (61,054)     $ 10,415 $ (71,469)    
Balance (in shares) at Dec. 31, 2020   95,010,858          
Balance at Dec. 31, 2020   $ 128,286          
Balance (in shares) at Dec. 31, 2020           1,576,137  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss (64,851)       (64,851)    
Issuance of Series D convertible preferred stock, net of issuance costs   $ 30,461          
Issuance of Series D convertible preferred stock, net of issuance costs (in shares)   14,171,333          
Investment from 4Bionics, LLC 3,516     3,516      
Conversion of Liminal Common stock (9,350)     (9,350)      
Conversion of Liminal Common stock (in shares)     57,500,000        
Conversion of Liminal Common stock     $ 9,350        
Conversion of Liminal Common stock (in shares)           (180)  
Exercise of stock options 1,497     1,497      
Exercise of stock options (in shares)           565,533  
Conversion of the convertible preferred stock into Class A and Class B common stock at the Business Combination 168,097 $ (158,747) $ (9,350) 168,092   $ 3 $ 2
Conversion of the convertible preferred stock into Class A and Class B common stock at the Business Combination (in shares)   (109,182,191) (57,500,000)     31,028,815 15,055,288
Net equity infusion from the Business Combination 141,471     141,469   $ 2  
Net equity infusion from the Business Combination (in shares)           21,806,756  
Issuance of Class A common stock to a service provider (in shares)           300,000  
Stock-based compensation expense 6,901     6,901      
Balance at Dec. 31, 2021 186,227         $ 5 $ 2
Balance at Dec. 31, 2021       322,540 (136,320)    
Balance (in shares) at Dec. 31, 2021           55,277,061 15,055,288
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss (73,164)       (73,164)    
Exercise of stock options 7     7      
Exercise of stock options (in shares)           25,870  
Issuance of restricted stock           319,557  
Stock-based compensation expense 10,652     10,652      
Balance at Dec. 31, 2022 $ 123,722         $ 5 $ 2
Balance (in shares) at Dec. 31, 2022     0        
Balance at Dec. 31, 2022       $ 333,199 $ (209,484)    
Balance (in shares) at Dec. 31, 2022           55,622,488 15,055,288